Crohn's disease patients have more IgG-binding fecal bacteria than controls

Clinical and Vaccine Immunology

Volumn 19, Issue 4, 2012, Pages 515-521

  Harmsen, Hermie J M ^a   Pouwels, Simon D ^a   Funke, Anouk ^a   Bos, Nicolaas A ^a   Dijkstra, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD SAMPLING; CONTROLLED STUDY; CROHN DISEASE; ESCHERICHIA COLI; FECES ANALYSIS; FECES LEVEL; FECES MICROFLORA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HOST PATHOGEN INTERACTION; HOST RANGE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SPECIES COMPOSITION; UPREGULATION;

ADULT; AGED; ANTIBODIES, BACTERIAL; CROHN DISEASE; ENTEROBACTERIACEAE; FECES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84859340946     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05517-11     Document Type: Article

References (36)

1. Amann RI, et al. 1990. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl. Environ. Microbiol. 56:1919-1925. (Pubitemid 20202165)
2. Barnich N, Darfeuille-Michaud A. 2007. Adherent-invasive Escherichia coli and Crohn's disease. Curr. Opin. Gastroenterol. 23:16-20. doi: 10.1097/MOG.0b013e3280105a38. (Pubitemid 44875904)
3. Franks AH, et al. 1998. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl. Environ. Microbiol. 64: 3336-3345. (Pubitemid 28411456)
4. Gebhard RL, et al. 1982. Acute viral enteritis and exacerbations of inflammatory bowel disease. Gastroenterology 83:1207-1209. (Pubitemid 13235919)
5. Gradel KO, et al. 2009. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 137:495-501.
6. Harmsen HJM, Raangs GC, He T, Degener JE, Welling GW. 2002. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl. Environ. Microbiol. 68:2982-2990. (Pubitemid 34602022)
7. Harmsen HJM, et al. 2000. Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age groups. Appl. Environ. Microbiol. 66:4523-4527.
8. Hunter JO. 1998. Nutritional factors in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 10:235-237. (Pubitemid 28175000)
9. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. 2001. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand. J. Gastroenterol. 36:291-296. (Pubitemid 32234579)
10. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. 2002. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 37:1034-1041.
11. Lapaquette P, Glasser A, Huett A, Xavier RJ, Darfeuille-Michaud A. 2010. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell. Microbiol. 12:99-113.
12. Manz W, Amann R, Ludwig W, Vancanneyt M, Schleifer KH. 1996. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum Cytophaga-Flavobacter- Bacteroides in the natural environment. Microbiology 142:1097-1106. (Pubitemid 26154919)
13. Mazmanian SK, Round JL, Kasper DL. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620-625. (Pubitemid 351769307)
14. Monteleone G, et al. 2006. Bacteria and mucosal immunity. Dig. Liver Dis. 38(Suppl. 2):S256-S260. (Pubitemid 46140764)
15. Poullis A, Foster R, Mendall MA, Fagerhol MK. 2003. Emerging role of calprotectin in gastroenterology. J. Gastroenterol. Hepatol. 18:756-762. (Pubitemid 36936565)
16. Poullis A, Foster R, Northfield TC, Mendall MA. 2002. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16:675-681. (Pubitemid 34407514)
17. Poulsen LK, Licht TR, Rang C, Krogfelt KA, Molin S. 1995. Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin- treated mice. J. Bacteriol. 177:5840-5845.
18. Qin J, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59-65.
19. Riordan AM, et al. 1993. Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 342:1131-1134. (Pubitemid 23324052)
20. Roseth AG, Aadland E, Jahnsen J, Raknerud N. 1997. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58:176-180. (Pubitemid 27163169)
21. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. 1992. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 27:793-798.
22. Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. 1999. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117:1089-1097. (Pubitemid 29512667)
23. Sipponen T, et al. 2008. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm. Bowel Dis. 14:1392-1398.
24. Sokol H, et al. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 105:16731-16736.
25. Sokol H, et al. 2009. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15:1183-1189.
26. Suau A, et al. 2001. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst. Appl. Microbiol. 24:139-145. (Pubitemid 32433703)
27. Swidsinski A, et al. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54. (Pubitemid 34049193)
28. Tamboli CP, Neut C, Desreumaux P, Colombel JF. 2004. Dysbiosis as a prerequisite for IBD. Gut 53:1057.
29. Thjodleifsson B, et al. 2003. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 124:1728-1737. (Pubitemid 36666769)
30. van der Waaij, LA, et al. 2005. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm. Bowel Dis. 11:865-871.
31. van der Waaij, LA, et al. 2004. Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 16:669-674.
32. Waar K, Degener JE, van Luyn MJ, Harmsen HJ. 2005. Fluorescent in situ hybridization with specific DNA probes offers adequate detection of Enterococcus faecalis and Enterococcus faecium in clinical samples. J. Med. Microbiol. 54:937-944. (Pubitemid 41395850)
33. Walker A, et al. 2011. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11:7.
34. Wapenaar MC, et al. 2008. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis: an unusual case of ascites. Gut 57:463-467. (Pubitemid 351442527)
35. Willing B, et al. 2009. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. In- flamm. Bowel Dis. 15:653-660.
36. Xavier RJ, Podolsky DK. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434. (Pubitemid 47123518)